Mesoblast completes 350-patient Phase 3 treatment as mid-2027 back pain readout becomes next valuation test

Mesoblast Limited (ASX: MSB; Nasdaq: MESO) has completed treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain caused by inflammatory degenerative disc disease, moving one of the biotechnology company’s largest potential indications into its final 12-month follow-up period. The trial was originally designed around 300 patients, but Mesoblast increased treatment to 350 after what it described as strong investigator demand, expanding the study population by approximately 16.7%. No efficacy results were released with the August 17 milestone, making the distinction between operational completion and clinical success particularly important. The next decisive catalyst is expected in mid-2027, when top-line data should show whether a single intra-discal cell therapy injection can deliver a statistically and clinically meaningful reduction in pain compared with a sham procedure.

Mesoblast shares were trading around A$2.34 on August 17, up about 6% from the previous A$2.21 close after moving between approximately A$2.19 and A$2.36 during the session. That still leaves the stock roughly 10% below its A$2.61 July 17 close and materially below its A$3.31 52-week high, although it has recovered substantially from the A$1.88 annual low. The mixed market picture reflects a company whose risk profile has changed significantly since Ryoncil became a commercial product, but whose valuation still contains major clinical-development exposure.

That combination makes the back-pain program strategically more important than a conventional pipeline update. Mesoblast generated US$115 million of Ryoncil net revenue during its first full financial year of launch and ended June with US$103 million of cash, while net operating cash spend for FY26 was US$43.8 million. The commercial business therefore provides considerably more financial support for late-stage development than Mesoblast had during earlier periods when clinical programs depended more heavily on external financing.

What exactly has Mesoblast completed in the 350-patient Phase 3 back pain trial?

The August 17 milestone means all 350 patients in the MSB-DR004 study have now been randomised and treated with either rexlemestrocel-L delivered into the affected lumbar disc or a sham procedure. It does not mean those patients have completed the full trial, nor does it provide evidence yet that rexlemestrocel-L is superior to the control arm. Each participant still needs to reach the relevant follow-up periods, with the primary analysis centred on pain reduction at 12 months.

Mesoblast initially designed the study for 300 patients. Increasing treatment to 350 adds 50 participants, or approximately 16.7%, to the original target. The company attributed that expansion to strong demand from trial investigators seeking to enrol patients, rather than to any interim efficacy finding. Because the study remains blinded, investor interpretation should therefore remain focused on improved sample size and trial execution rather than assuming investigator enthusiasm predicts a positive outcome.

The primary endpoint is straightforward but demanding: the study must demonstrate a meaningful difference in reduction of low back pain at 12 months between rexlemestrocel-L and the control group. Secondary measures include physical function, quality of life and cessation of pain medication, including opioids.

That endpoint structure is important commercially. Chronic back-pain trials can be complicated by subjective symptom reporting, strong placebo responses and multiple competing causes of pain. A sham-controlled design provides a higher evidentiary hurdle than an uncontrolled study because patients in both arms experience a procedure, helping separate treatment effect from expectations surrounding intervention.

For Mesoblast, trial completion therefore removes one category of execution risk while leaving the larger biological risk intact. Recruitment and treatment are finished. The company now needs the underlying data to justify the years of clinical development that preceded the study.

Why does the FDA’s agreement on the 12-month pain endpoint matter for rexlemestrocel-L?

Mesoblast already has an unusually clear regulatory framework for the study. The United States Food and Drug Administration has agreed with the design of the confirmatory Phase 3 trial and with pain reduction at 12 months as an endpoint capable of supporting an approvable indication if the data are sufficiently persuasive. Rexlemestrocel-L also holds Regenerative Medicine Advanced Therapy designation for chronic low back pain associated with degenerative disc disease.

That does not mean FDA approval has been pre-agreed. Regulatory alignment on trial design answers a different question: whether Mesoblast is measuring an endpoint the agency considers relevant for a potential application. The trial still has to produce an adequate treatment effect with an acceptable safety profile, and the eventual Biologics License Application would still undergo regulatory review.

The distinction is particularly important because RMAT designation can sometimes be misinterpreted as an indication of likely approval. It provides benefits associated with expedited development, including closer regulatory interaction, rolling-review potential and eligibility for priority review once an application is filed. It does not eliminate the requirement to demonstrate efficacy, safety and manufacturing consistency.

January 2026 FDA feedback provided another useful signal. According to Mesoblast’s disclosure, the agency acknowledged that pain-intensity effects in the earlier Phase 3 study favoured the rexlemestrocel-L arm and indicated that a clinically meaningful reduction in pain at 12 months could support efficacy for a future application. The FDA also indicated that robust opioid-reduction findings from an adequate and well-controlled trial could potentially be included in the Clinical Studies section of product labelling.

For investors, this means MSB-DR004 is not merely an exploratory study hoping to discover which endpoint regulators might accept later. The regulatory question is relatively well framed. What remains unknown is whether 350 randomised patients will generate the required clinical result.

What did Mesoblast’s earlier Phase 3 back pain study actually show?

The current study is designed to confirm observations from the earlier MSB-DR003 Phase 3 trial, which enrolled 404 patients. Mesoblast has reported that pain reduction at 12 months was achieved in the earlier study, providing part of the rationale for using pain as the primary endpoint in MSB-DR004.

One of the more commercially interesting findings involved opioid use. Among 168 participants who were taking opioids at baseline, Mesoblast reported that more than three times as many patients receiving rexlemestrocel-L with hyaluronic acid were able to stop all opioid use by 36 months compared with saline-treated controls, with a reported p-value of 0.008.

That result helps explain why opioid cessation remains a secondary endpoint in the current study. A treatment that reduces pain but requires continued dependence on substantial pain medication would have a different value proposition from one that produces durable symptom improvement while reducing medication requirements.

However, the present Phase 3 trial still needs to reproduce the central pain benefit prospectively under its agreed statistical design. Findings from a previous trial can establish biological and regulatory rationale, but they do not guarantee replication. That is exactly why confirmatory trials exist.

The inclusion criteria also narrow the population being tested. Rexlemestrocel-L is being studied in patients with moderate to severe chronic low back pain associated with inflammatory degenerative disc disease of less than five years’ duration who have not achieved adequate relief from conservative treatment. This is therefore not a trial of every form of chronic back pain.

That precision should eventually help define the commercial population if the therapy succeeds. It also means estimates based on the entire chronic back-pain population should not automatically be treated as the addressable market for rexlemestrocel-L.

Could rexlemestrocel-L become commercially larger than Mesoblast’s existing Ryoncil business?

Mesoblast describes the opportunity as potentially very large, citing more than seven million people in the United States with chronic low back pain associated with inflammation and degenerative disc disease. The company has also suggested that the indication could ultimately support peak annual revenue above US$10 billion with single-digit market penetration. That figure is a management scenario rather than independently established future revenue and depends on clinical success, regulatory approval, pricing, reimbursement, physician adoption, eligible-patient identification and manufacturing capacity.

Even without accepting the US$10 billion scenario literally, the commercial logic is clear. Ryoncil currently addresses a relatively specialised population of paediatric patients with steroid-refractory acute graft-versus-host disease. Chronic degenerative low back pain is a much broader condition, potentially giving rexlemestrocel-L access to a market with far greater patient numbers if its benefit-risk profile supports widespread adoption.

The route to commercialisation would nevertheless be more complicated than patient prevalence suggests. Rexlemestrocel-L is administered through an intra-discal injection rather than a conventional tablet or routine intravenous infusion. Commercial adoption would therefore depend on appropriate specialist referral, procedural capacity, reimbursement arrangements and physician confidence that the benefit of a one-time biological intervention justifies the procedure.

Pricing will matter as well. A regenerative cell therapy might command substantially more per treatment than ordinary chronic-pain medication, but insurers would likely evaluate whether durable pain reduction, improved function and reduced medication use offset the upfront cost. Evidence of sustained benefit could consequently be as commercially important as statistical significance at the primary endpoint.

The mid-2027 readout will therefore answer only the first major commercial question. A positive trial would shift attention toward regulatory review, product labelling, manufacturing readiness, pricing and market access.

How does Ryoncil’s US$115 million first-year revenue change Mesoblast’s clinical-development risk?

This is one of the most important differences between the Mesoblast entering MSB-DR004 and the Mesoblast that conducted earlier late-stage studies. Ryoncil generated US$36 million of net revenue during the June quarter and US$115 million across its first full financial year following commercial launch. Mesoblast ended June 30 with US$103 million of cash.

The financial improvement does not make late-stage biotechnology development inexpensive. Mesoblast still recorded US$43.8 million of net operating cash spend during FY26 and has several clinical and commercial programs competing for capital. Yet second-half operating cash spend fell to US$13.4 million as Ryoncil receipts increased, illustrating how product revenue can begin supporting the pipeline rather than the pipeline depending entirely on repeated equity financing.

The company also drew US$50 million from an existing five-year financing facility before June 30 and used the broader financing structure to extinguish maturing debt obligations. The facility carries an 8% fixed interest rate and is secured solely against the Temcell royalty following repayment of the previous debt structure, according to company disclosures.

That capital position gives Mesoblast more flexibility as it waits for the back-pain readout. The company can continue building commercial manufacturing and supporting other registration programs without the same immediate dependence on a single binary financing event.

The trade-off is that Mesoblast is no longer a simple one-program biotechnology story. Ryoncil’s commercial expansion into additional indications, rexlemestrocel-L programs in heart failure and chronic back pain, manufacturing investment and debt management all compete for management attention and cash. Stronger resources reduce financing risk, but they also make capital-allocation discipline more important.

Why did Mesoblast shares rise only modestly after completing treatment of 350 patients?

Mesoblast was trading around A$2.34 on August 17, approximately 6% above the previous A$2.21 close. The movement was positive but far smaller than investors might expect from a genuinely positive pivotal efficacy readout, which is appropriate because no efficacy data were released.

The stock also remains below recent levels. Mesoblast closed at A$2.61 on July 17, placing the August 17 price roughly 10% lower over one month. Against the A$3.31 52-week high, the stock is down around 29%, while it remains approximately 25% above the A$1.88 annual low.

That range suggests investors are assigning meaningful value to Ryoncil commercialisation and Mesoblast’s late-stage pipeline without pricing the back-pain program as though success were assured. At approximately A$2.34 and around 1.3 billion shares outstanding, Mesoblast carries an equity market value of roughly A$3 billion.

The current valuation therefore already reflects more than the US$115 million Ryoncil revenue base. Investors are also valuing potential Ryoncil label expansion and the probability-weighted value of rexlemestrocel-L across multiple indications.

The mid-2027 back-pain readout could materially change that probability weighting in either direction. Positive data would move the discussion from clinical probability toward regulatory filing and commercial economics. A failed primary endpoint would remove much of the chronic back-pain opportunity from near-term valuation while leaving Ryoncil and other rexlemestrocel-L programs intact.

What are the key takeaways from Mesoblast’s 350-patient Phase 3 treatment milestone?

• Mesoblast has completed treatment of 350 patients in its pivotal MSB-DR004 Phase 3 chronic low back pain trial.
• The trial originally targeted 300 patients, meaning the final treated population is approximately 16.7% larger than initially planned.
• Patients were randomised to receive a single intra-discal injection of rexlemestrocel-L or a sham procedure.
• No efficacy results were released on August 17, so treatment completion should not be interpreted as evidence that the trial has succeeded.
• The primary endpoint evaluates pain reduction at 12 months, with top-line results expected in mid-2027.
• The FDA has agreed with the pivotal study design and with 12-month pain reduction as an endpoint capable of supporting an approvable indication if the data are adequate.
• Rexlemestrocel-L holds FDA Regenerative Medicine Advanced Therapy designation, providing expedited-development benefits but not guaranteeing approval.
• Mesoblast’s earlier 404-patient Phase 3 study produced supportive pain findings and reported significant long-term opioid-cessation results in baseline opioid users.
• Ryoncil generated US$115 million of net revenue in FY26, while Mesoblast ended June with US$103 million of cash.
• Mesoblast shares were around A$2.34 on August 17, up about 6% for the session but still roughly 10% below their July 17 close.

What will determine whether rexlemestrocel-L becomes Mesoblast’s next commercial platform?

Completing treatment of 350 patients removes a meaningful operational hurdle from Mesoblast’s chronic low back pain program. Recruitment delays, treatment logistics and site execution can derail even promising late-stage studies, and those risks are now largely behind MSB-DR004. The company has also entered the waiting period with an FDA-approved commercial product generating significant revenue, making its financial position materially stronger than during earlier phases of the rexlemestrocel-L program.

What has not changed is the binary clinical test. The study must demonstrate that patients receiving rexlemestrocel-L experience a sufficiently greater reduction in pain at 12 months than those undergoing the sham procedure. Neither the additional 50 patients nor RMAT designation substitutes for that evidence.

A positive result would be strategically significant because it could broaden Mesoblast from a company commercialising a specialist paediatric inflammatory therapy into one pursuing a potentially much larger chronic-disease market. The regulatory groundwork is comparatively clear, manufacturing preparations are progressing in parallel and the company has previously indicated its intention to move quickly toward a Biologics License Application following a successful readout.

The stronger investment thesis would therefore require more than statistical significance. Investors would want a clinically persuasive magnitude of pain reduction, supportive functional outcomes, durable benefit, acceptable safety and evidence that opioid use can be reduced in an appropriately controlled population. Those data would determine whether rexlemestrocel-L can justify the commercial scale Mesoblast envisages.

Until then, August 17 represents an important execution milestone rather than a clinical verdict. Mesoblast has finished treating the patients. Mid-2027 is when investors find out whether the treatment worked.